COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,893 Articles (22,568 medRxiv, 8,325 bioRxiv)

Most recent first Previous |  Page 2392: Articles 23911-23920  | Next

New Insights on Excess Deaths and COVID-19
Wetzler, H. P., Cobb, H. W.
10.1101/2020.07.24.20051508 — Posted: 2020-07-27
An effective COVID-19 response in South America: the Uruguayan Conundrum
Moreno, P., Moratorio, G. A., Iraola, G., Fajardo, A., Aldunate, F., Pereira, M., Perbolianachis, P., Costabile, A., Lopez-Tort, F., Simon, D., Salazar, C., Ferres, I., Diaz-Viraque, F., Abin, A., Bresque, M., Fabregat, M., Maidana, M., Rivera, B., Cruces, M., Rodriguez, J., Scavone, P., Alegretti, M., Nabon, A., Gagliano, G., Rosa, R., Henderson, E., Bidegain, E., Zarantonelli, L., Piattoni, C., Greif, G., Francia, M., Robello, C., Duran, R., Brito, G., Bonnecarrere, V., Sierra, M., Colina, R., Marin, M., Cristina, J., Erlich, R., Paganini, F., Cohen, H., Radi, R., Barbeito, L., Badano, J., Pritsch, O., Fernandez, C., Arim, R., Batthyany, C., Interinstitutional COVID-19 Working Group
10.1101/2020.07.24.20161802 — Posted: 2020-07-27
Predicting Critical State after COVID-19 Diagnosis Using Real-World Data from 20152 Confirmed US Cases
Rinderknecht, M. D., Klopfenstein, Y.
10.1101/2020.07.24.20155192 — Posted: 2020-07-27
Why (and how) COVID-19 could move us closer to the "health information for all" goal
Capocasa, M., Destro Bisol, G., Anagnostou, P.
10.1101/2020.07.23.20160481 — Posted: 2020-07-27
Effects of non-pharmaceutical interventions on COVID-19: A Tale of Two Models
Chin, V., Ioannidis, J., Tanner, M., Cripps, S.
10.1101/2020.07.22.20160341 — Posted: 2020-07-27 Discussion: Onsite
COVID-19 and Rheumatoid Arthritis share myeloid pathogenic and resolving pathways
MacDonald, L., Otto, T. D., Elmesmari, A., Tolusso, B., Somma, D., McSharry, C., Gremese, E., McInnes, I. B., Alivernini, S., Kurowska-Stolarska, M.
10.1101/2020.07.26.221572 — Posted: 2020-07-26 Discussion: Onsite | Offsite
Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as vaccine candidate
Sun, W., Leist, S. R., McCroskery, S., Liu, Y., Slamanig, S., Oliva, J., Amanat, F., Schaefer, A., Dinnon, K., Garcia-Sastre, A., Krammer, F., Baric, R. S., Palese, P.
10.1101/2020.07.26.221861 — Posted: 2020-07-26 Discussion: Onsite | Offsite
The SARS-CoV-2 Spike Variant D614G Favors an Open Conformational State
Mansbach, R. A., Chakraborty, S., Nguyen, K., Montefiori, D., Korber, B., Gnanakaran, S.
10.1101/2020.07.26.219741 — Posted: 2020-07-26
No evidence for basigin/CD147 as a direct SARS-CoV-2 spike binding receptor
Shilts, J., Wright, G. J.
10.1101/2020.07.25.221036 — Posted: 2020-07-26 Discussion: Onsite
Systematic evaluation and external validation of 22 prognostic models among hospitalised adults with COVID-19: An observational cohort study
Gupta, R. K., Marks, M., Samuels, T. H. A., Luintel, A., Rampling, T., Chowdhury, H., Quartagno, M., Nair, A., Lipman, M., Abubakar, I., van Smeden, M., Wong, W. K., Williams, B., Noursadeghi, M.
10.1101/2020.07.24.20149815 — Posted: 2020-07-26 Discussion: Onsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).